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TO THE EDITOR: In their recent article in Journal of Clinical
Oncology, Rajyaguru et al1 report on a retrospective comparison of
two local ablative methods (stereotactic body radiotherapy [SBRT]
and radiofrequency ablation [RFA]) for the management of lo-
calized hepatocellular carcinoma (HCC) using the National Cancer
Database. The authors ﬁnd that overall survival is better in the RFA
than in the SBRT cohort, even when some parameters are matched.
For the comparison of effectiveness of local ablative methods,
prospective randomized studies are still missing, and hence, ret-
rospective analyses of large databases such as the study by
Rajyaguru et al are relevant as the best evidence at hand. This
study is speciﬁcally impressive because it reports data on almost
4,000 patients. However, although some limitations are discussed
by the authors, several major limitations remain unaddressed,
which we would like to highlight.
First, the major weakness of the study design is that in-
formation on the liver function of patients is missing (ie, Child-
Turcotte-Pugh [CTP] score, which is the predominant prognostic
factor, because a majority of patients die as a result of liver failure
and portal hypertension). Moreover, data on Barcelona Clinic Liver
Cancer stage and presence of portal vein invasion are also missing.
The authors attempt to compensate for missing CTP score by
providing the Ishak ﬁbrosis score, although this information is
available for few patients (SBRT, 16%; RFA, 29%). However, the
prognostic value of the Ishak score is low compared with that of
CTP score,2 and comorbidity scores also cannot compensate for
missing CTP score. Finally, clinical TNM stage I and II data are
assumed to represent exclusively T stage, ignoring N stage, and not
to represent prognostic stage groups I or II. Therefore, the authors’
matched pair analysis explores only minor prognostic variables and
thus cannot achieve properly matched patient cohorts. We suspect
that the difference in survival reported is a result of selection bias,
mainly resulting from imbalanced CTP scores and Barcelona Clinic
Liver Cancer stages.
Second, this analysis excludes patients receiving any form of
adjuvant or neoadjuvant therapy or other forms of local ablative
therapies. This is intriguing, because the typical course of the disease
almost inadvertently requires further treatment, as discussed by the
authors. This exclusion raises important uncertainties about patient
selection, because it does not reﬂect common practice.
Third, regarding patient numbers, there is a major imbalance
between the two treatment arms (SBRT, n5 296 v RFA, n5 3,684),
which underlines the risk of a major selection bias. One has to
assume that only patients who were not candidates for other
treatment options were referred for SBRT. Interestingly, patients
receiving RFA were more likely to have private insurance, and
they were younger compared with patients receiving SBRT. Both
of these factors would have a direct impact on survival.
Fourth, much of the authors’ discussion focuses on local
control (LC) after RFA and SBRT, and interestingly, the authors
state that LC in HCCmay not translate into improved progression-
free or overall survival. Unfortunately, no data on LC are reported
in this analysis to prove this hypothesis, which would, if true, favor
neither RFA nor SBRT. However, SBRT and RFA are local ablative
therapies, and multiple recent publications conclude that even
though SBRT shows an advantage for larger tumors, both tech-
niques result in the same LC rates.3,4
Fifth, the data presented originate from the years between 2003
and 2014. SBRTat that time (2003 to 2010) was in the early phase of
development and optimization (ie, there was no standardized
technique or radiation dose for liver tumors). In contrast, there are
now widely accepted guidelines5 and reports that advanced tech-
nologies for liver SBRT and the use of sufﬁciently high radiation
doses are signiﬁcantly associated with improved outcomes, perhaps
even exceeding those achievable with RFA,3,6 with low toxicity7 and
good quality of life.8 Proper knowledge of SBRT details regarding
prescription dose, motion management, and image guidance as well
as their correlation with LC is therefore of paramount importance in
interpreting these outcome data.
In summary, Rajyaguru et al1 report rather surprising dif-
ferences in survival between RFA and SBRT. A closer look at their
work reveals that a number of highly important prognosis factors
for patients with HCC are not taken into consideration in the
statistical analysis. Therefore, we would like to emphasize these
weaknesses and suggest that physicians treating HCC contribute to
prospective randomized trials that compare the two methods.
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